32 /100
MEDIUM RISK
Score updated Jul 13, 2026

IRWD — Ironwood Pharmaceuticals, Inc. Dilution Risk Tracker

Track IRWD dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track IRWD — Get alerts when the score changes →

As of July 13, 2026, Ironwood Pharmaceuticals, Inc. (IRWD) has a DilutionWatch DilutionScore of 32/100, rated MEDIUM dilution risk. Ironwood Pharmaceuticals, Inc. has a market capitalization of $587.67M, 164.61M shares outstanding, 227 institutional holders tracked. Key dilution vectors include approximately 999 months of cash runway.

Source: DilutionWatch (dilutionwatch.com) — data updated daily from SEC EDGAR filings. Not financial advice.

📊 Score Breakdown

📋 Offering Ability
40
💰 Cash Runway
0
📊 Float Risk
22
⚠️ Warrant Exposure
40
🔄Convertible Debt

🌦️ Dilution Forecast

⛈️
Warning
High probability of dilution event
34%
🔁 Convertible Conversion 60%
• Major convertible overhang: 68% potential dilution
• Convertible risk score very high (85/100)
🔄 Reverse Split 15%
• 52-week low $0.56 has breached $1
🔔 Track IRWD — Get forecast alerts →

💹 Market Data

Market Cap$587.67M
Shares Outstanding164.61M
Float136.34M
Cash$220.47M
Debt$320.21M
Short InterestN/A

🏛 Institutional Holdings

QoQ: ↑ 6.7% shares (2026Q1 vs prior)
227 institutional holders · 190.05M shares
#1 ARMISTICE CAPITAL, LLC 15.03M shares
#2 BlackRock, Inc. 13.36M shares
#3 VANGUARD CAPITAL MANAGEMENT LLC 12.19M shares
+ 17 more holders Sign up free to view →

📉 Short Interest

Short Interest16.23M
Days to Cover5.7
% of Float11.9%
FINRA data as of Jun 30, 2026

📁 Recent SEC Activity

xbrl XBRL WARRANT Dec 31, 2023
xbrl XBRL CONVERTIBLE Dec 31, 2019
4 INSIDER TRANSACTION Mar 17, 2026
4 INSIDER TRANSACTION Mar 12, 2026
4 INSIDER TRANSACTION Mar 12, 2026
Full SEC filing analysis available with free account

📰 Recent News

No recent news

📋 What This Means for IRWD Shareholders

Ironwood Pharmaceuticals, Inc. (IRWD) has a DilutionScore of 32/100, rated Medium dilution risk. This tier indicates some dilution exposure — often an older shelf registration with remaining capacity, warrants not yet exercised, or a cash position that will require monitoring over the next several quarters. Score as of July 13, 2026.

DilutionWatch's EDGAR monitoring for IRWD shows no major active dilution programs at this time. The primary risk categories — shelf registration capacity, ATM programs, warrant overhang, and cash runway — are each within normal ranges for a company of this profile. This can change quickly if a new S-3 or Form S-1 is filed.

DilutionWatch tracks over 25 SEC filing types for IRWD in real-time, scanning EDGAR every 60 seconds. The DilutionWatch screener shows real-time score changes for IRWD alongside comparable medium-risk stocks. Not financial advice — this analysis is for informational purposes only.

Track IRWD Dilution Risk in Real-Time
Get instant alerts when SEC filings impact dilution risk. Free tier available.
Start Tracking IRWD — Free
Real-time SEC alerts DilutionScore™ tracking No credit card required

🔗 Related Stocks — MEDIUM Risk

Other MEDIUM dilution risk stocks tracked by DilutionWatch with similar profiles:

Browse all 7,800+ tracked stocks →

📖 Dilution Education
→ Complete Dilution Guide for Retail Investors → Anti-Dilution Provisions Explained → Stock Dilution Red Flags to Watch → Understanding Shelf Registrations
🔬 More Research for IRWD
📊 IRWD FDA Catalyst Timeline & Biotech Grade — BiotechSigns 📡 IRWD Signal Convergence & Dark Pool Activity — StonkWhisper

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.